Stryker Corporation $SYK Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lifted its position in Stryker Corporation (NYSE:SYK) by 7.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,062 shares of the medical technology company’s stock after buying an additional 1,700 shares during the period. Oppenheimer & Co. Inc.’s holdings in Stryker were worth $8,205,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares in the last quarter. State Street Corp raised its position in Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Stryker during the 4th quarter valued at about $1,822,272,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on SYK. Needham & Company LLC lowered their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Barclays cut their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. Finally, UBS Group assumed coverage on Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Performance

Shares of SYK opened at $338.80 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a 50-day moving average of $324.61 and a two-hundred day moving average of $333.57. The stock has a market cap of $129.95 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.